Annals of Epidemiology
Volume 17, Issue 8 , Pages 584-590 , August 2007

A Refined Comorbidity Measurement Algorithm for Claims-Based Studies of Breast, Prostate, Colorectal, and Lung Cancer Patients

Received 25 October 2006 ,Accepted 5 March 2007.

References 

  1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–383
  2. Klabunde CN, Warren JL, Legler JM. Assessment of comorbidity using claims data: an overview. Med Care. 2002;40(Suppl):26–35
  3. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619
  4. Romano PS, Roos LL, Luft HS, Jollis JG, Doliszny K. A comparison of administrative versus clinical data: coronary artery bypass surgery as an example. J Clin Epidemiol. 1994;47:249–260
  5. Bernstein AB, Hing E, Burt CW, Hall MJ. Trend data on medical encounters: tracking a moving target. Health Aff. 2001;20:58–72
  6. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258–1267
  7. Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat. 2006;99:313–321
  8. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23:8597–8605
  9. Haggstrom DA, Quale C, Smith-Bindman R. Differences in the quality of breast cancer care among vulnerable populations. Cancer. 2005;104:2347–2358
  10. Piccirillo JF, Spitznagel EL, Vermani N, Costas I, Schnitzler M. Comparison of comorbidity indices for patients with head and neck cancer. Med Care. 2004;42:482–486
  11. Gold HT, Dick AW. Variations in treatment for ductal carcinoma in situ in elderly women. Med Care. 2004;42:267–275
  12. Shavers VL, Brown M, Klabunde CN, Potosky AL, Davis W, Moul J, et al. Race/ethnicity and the intensity of medical monitoring under ‘watchful waiting’ for prostate cancer. Med Care. 2004;42:239–250
  13. Shavers VL, Brown ML, Potosky AL, Klabunde CN, Davis WW, Moul JW, et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med. 2004;19:146–155
  14. Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004;64:1171–1176
  15. Fleming ST, Rastogi A, Dmitrienko A, Johnson KD. A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care. 1999;37:601–614
  16. Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol. 2000;29:891–898
  17. Fleming ST, Pearce KA, McDavid K, Pavlov D. The development and validation of a comorbidity index for prostate cancer among Black men. J Clin Epidemiol. 2003;56:1064–1075
  18. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732–748
  19. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40;(Suppl): IV-3–IV-18
  20. Centers for Medicare and Medicaid Services. Provider Reimbursement Manual. Available at: http://www.cms.hhs.gov/manuals/cmsindex.asp. Accessed April 10, 2007.
  21. Fritz A, Percy C, Jack A, Sobin L, Parkin M. In: International Classification of Diseases for Oncology. 3rd ed.. Geneva: World Health Organization; 2000;
  22. National Cancer Institute, Health Services and Economics Branch. SEER-Medicare: Calculation of Comorbidity Weights. Available at: http://healthservices.cancer.gov/seermedicare/program/comorbidity.html. Accessed April 10, 2007.
  23. Klabunde CN, Harlan LC, Warren JL. Data sources for measuring comorbidity: a comparison of hospital records and Medicare claims for cancer patients. Med Care. 2006;44:921–928
  24. Young JL. SEER Summary Staging Manual 2000: Codes and Coding Instructions. Bethesda, MD: NIH Publication No. 01-4969; 2000.
  25. Fleming TR, Harrington DP. Counting Processes and Survival Analysis. New York: John Wiley & Sons; 1991;
  26. Baldwin LM, Klabunde CN, Green P, Barlow W, Wright GE. In search of the perfect comorbidity measure for use with administrative claims data: does it exist?. Med Care. 2006;44:745–753

PII: S1047-2797(07)00145-7

doi: 10.1016/j.annepidem.2007.03.011

Annals of Epidemiology
Volume 17, Issue 8 , Pages 584-590 , August 2007

Article Tools